OBiO Technology, a contract development and manufacturing organization (CDMO) for cell and gene therapy, entered into an agreement with Refreshgene Therapeutics. Under the agreement, OBiO will leverage its capabilities of process development, large-scale cGMP commercial production and global business development to provide high-quality CDMO/CMO services and authorized cooperation services for Refreshgene’s RRG-001 pipeline, and jointly promote the development of advanced therapies to benef...